https://store-images.s-microsoft.com/image/apps.55966.dd120128-e5f3-4f4d-a6bf-7011d1762e98.b1666455-2b2e-426d-bf32-7734b236fd10.136dbef6-105b-4259-a668-e742da28862b

AI-driven neuroimaging solutions for clinical trials

IXICO Technologies Limited

AI-driven neuroimaging solutions for clinical trials

IXICO Technologies Limited

End-to-end management and analysis of your neuroimaging clinical trials powered by expertise & AI in

IXICO combines proven imaging CRO capabilities with AI-driven neuroimaging solutions and a scalable technology platform to provide end-to-end solutions for imaging studies in central nervous systems (CNS) clinical trials. With our expertise in global site operations management, we have developed a track record in working with imaging sites across the globe in our support of clinical trials across phases.

Our cutting-edge AI-algorithms allow for automatic measuring and quantification of brain biomarkers, providing insights not available through visual interpretation. We combine this technology with our specialist neuroscience knowledge and highly curated neurological patient data to provide end-to-end imaging insights for CNS studies.

With our global expertise of setup and operations management, our network of highly trained and configured imaging sites, and our utilization of IXICO's TrialTracker platform for comprehensive regulatory-compliant image data management systems, we expedite the delivery of endpoints. This enables sponsors to address challenges and realize the full potential of imaging biomarkers in their CNS clinical trials.

Choose IXICO for AI-powered solutions that deliver meaningful neuroimaging insights and drive success in your CNS clinical trials.

Full Analysis utilizing our AI-driven platforms

- Radiology Eligibility and Safety Visual Reads

Across a wide range of Imaging Modalities

MRI:

  • Volumetrics (Structural T1, T2, Lesion Mapping for the Brain and Spine)
  • Diffusion MRI (dMRI)
  • Perfusion - Arterial Spin Labelling (ASL)
  • BOLD (fMRI), Metabolites (MRS)
  • Susceptibility (QSM)
  • Neuromelanin

PET & SPECT:

  • Dopamine
  • Amyloid
  • Tau
  • Glucouse
  • Inflammation
  • α-synuclein

End-to-end neuroimaging analysis and management, tailored to your needs.

Our AI-driven platforms and therapeutic expertise accelerate the speed to insights, from early-phase development to post-marketing surveillance. Get faster trial outcomes and conclusions with IXICO with these capabilities:

  • Study Design & Consultation
  • Global Project Management
  • Global Imaging Site Setup & Operations Management

CNS Therapeutic expertise

Proven therapeutic expertise across major CNS indications including:

Common Diseases

Alzheimer’s Disease

Parkinson’s Disease

Multiple Sclerosis

Rare Diseases

Huntington’s Disease

Multiple System Atrophy

Progressive Supranuclear Palsy

• Ataxias including Friedreich’s Ataxia

Other Movement Disorders & Dementias

https://store-images.s-microsoft.com/image/apps.41973.dd120128-e5f3-4f4d-a6bf-7011d1762e98.b1666455-2b2e-426d-bf32-7734b236fd10.2b3fffbc-bc12-45c3-b8c0-77752a30b73c
https://store-images.s-microsoft.com/image/apps.41973.dd120128-e5f3-4f4d-a6bf-7011d1762e98.b1666455-2b2e-426d-bf32-7734b236fd10.2b3fffbc-bc12-45c3-b8c0-77752a30b73c
https://store-images.s-microsoft.com/image/apps.35735.dd120128-e5f3-4f4d-a6bf-7011d1762e98.b1666455-2b2e-426d-bf32-7734b236fd10.7fcba447-a08a-49ba-952e-601fe0d00bd3